Why tumor type changes interpretation
The clinical relevance of a biomarker depends on both the alteration and the cancer. For example, EGFR activating mutations are important in selected non-small-cell lung cancers, while HER2 status plays different roles across breast, gastric and other cancers.
Biomarkers require precise definitions
EGFR mutation subtypes, BRAF V600 alterations, KRAS variants, ERBB2 amplification versus mutation, microsatellite instability and gene fusions are not interchangeable. Assay methods and the exact molecular finding should be documented.
Linking molecular findings to evidence
Reviewing biomarker-directed therapy requires attention to the specific tumor indication, prior lines of treatment, comparator arms, outcomes, safety signals, and whether results are prospective, retrospective or exploratory.
Interpreting uncertain findings
Variants of uncertain significance and findings without disease-specific evidence should be distinguished from biomarkers with validated clinical utility. Evidence should be assessed as of the date of review.
Cancer-specific evidence maps
OncoAtlas provides research-oriented cancer-specific maps that can help locate relevant therapeutic evidence. Its content should be cross-checked against current primary studies, regulatory labels and guidelines.
Related resource: OncoAtlas cancer evidence maps. Published profile: OncoDaily feature.